{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-081792","form_type":"8-K","ticker":"CERO","cik":"0001870404","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2024-09-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.035225+00:00","generated_at":"2026-05-31T01:55:23.781363+00:00","sec_items":["1.01","3.02","5.02","8.01","9.01"],"event_type":"leadership","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"CERo raises $1.2M, CEO and CTO resign; CER-1236 on clinical hold","bullets":["CEO Brian Atwood resigns effective no later than Sep 30, 2024; CTO Daniel Corey resigns immediately.","Chris Ehrlich appointed interim Chairman and CEO; board searching for permanent replacement.","Raised ~$1.2M via private placement of Series C preferred stock and warrants at $1,000/share.","CER-1236 remains on clinical hold; Type A meeting with FDA requested to address two questions.","CFO Charles Carter also stepping down; cost reductions being implemented."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-081792","json":"https://secwatch.observer/filing/0001213900-24-081792.json","markdown":"https://secwatch.observer/filing/0001213900-24-081792.md","text":"https://secwatch.observer/filing/0001213900-24-081792.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024081792/0001213900-24-081792-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024081792/ea0215346-8k_cerothera.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T01:55:23.781363+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"294fcef3f9","claim":"Daniel Corey resigned as Chief Technology Officer at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"On September 23, 2024, the Company’s Chief Technology Officer and director, Daniel Corey, informed the Board of his resignation as Chief Technology Officer and director, effective immediately, to accept a new position on the faculty of the University of California, San Francisco.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024081792/0001213900-24-081792-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Technology Officer"}],"fact_type":"executive_change"},{"claim_id":"91340a313f","claim":"Chris Ehrlich was appointed as Interim Chairman and Chief Executive Officer at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"Chris Ehrlich, the Vice Chairman of the Board, agreed to serve as Interim Chairman and Chief Executive Officer while the Board searches for a permanent replacement.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024081792/0001213900-24-081792-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chairman and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"c76fa41ee8","claim":"Daniel Corey resigned as director at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"On September 23, 2024, the Company’s Chief Technology Officer and director, Daniel Corey, informed the Board of his resignation as Chief Technology Officer and director, effective immediately, to accept a new position on the faculty of the University of California, San Francisco.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024081792/0001213900-24-081792-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"d9a5d50e4e","claim":"Brian G. Atwood resigned as Chief Executive Officer at CERO THERAPEUTICS HOLDINGS, INC..","evidence_excerpt":"On September 22, 2024, the Company’s Chairman and Chief Executive Officer, Brian G. Atwood, informed the Board of his resignation as Chief Executive Officer, effective at a date to be determined, which shall be no later than September 30, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390024081792/0001213900-24-081792-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}